Medical Company's Concussion Treatment Clears FDA-Required Cardiotoxicity Testing
Oragenics Inc. and Their Recent Announcement on ONP-002.
Disclaimer: The following article aims to provide detailed and neutral information regarding Oragenics Inc.'s announcement about their concussion drug, ONP-002. This is for informational purposes only and should not be considered medical advice or a promotional endorsement.
Real-time information is available daily at https://stock…